BUFFALO, NY – A new editorial paper was published in Oncotarget’s Volume 14, entitled, “One more step toward treatment of PARP inhibitor-resistant ovarian cancers.” Over 80% of ovarian cancer cases experience recurrence, resulting in roughly 12,000 annual deaths in the United States. While targeted therapies like poly (ADPribose) polymerase inhibitors...
Latest News
Tel Aviv, Israel – In a first, Tel Aviv University researchers have discovered that the production and regulation of mitochondrial organelles in the brain’s nerve cells (neurons) becomes significantly impaired with the deletion of a gene called Gtf2i, one of the 25 genes deleted in Williams syndrome. This impairment is...
Basel — New results from a one-year Phase III study have confirmed that the investigational biological therapy Ilaris® (canakinumab, formerly ACZ885)[*] produced rapid and sustained remission of symptoms in the majority of children and adults with a rare and potentially life-threatening auto-inflammatory disease called cryopyrin-associated periodic syndrome (CAPS)[1],[2],[3]. The study...
An online symptom management tool that harnesses the problem-solving benefits of expressive writing could help women with ovarian cancer better manage complex symptoms, according to a new study led by a University of Pittsburgh and UPMC nurse-scientist. Published today in the Journal of Clinical Oncology, the study found that patients...
Hattie Foster looks up to the sky. She’s 6 years old. The sun is shining, and she’s buzzing with energy. “Where’s the moon?” she asks whomever is listening. Her older brother, 9-year-old Charlie, climbs across the nearby jungle gym at a Prairie Village playground as her younger brother, 3-year-old Will,...
PRINCETON, N.J. & ALAMEDA, Calif. — Bristol Myers Squibb and Exelixis, Inc. today announced four-year follow-up results from the CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) vs. sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC). Results continued to show superior progression-free...
Philadelphia, PA – Millions of people living with neurodegenerative diseases and their loved ones have long hoped for the day when treatments could change the prognosis from an inevitable decline to a managed, stable condition. The urgent need for life-changing therapies exists against the backdrop of a growing prevalence of...
SAN DIEGO, Calif. — Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics, presented promising preclinical data in two programs, OPN-6602, a dual EP300/CBP inhibitor in multiple myeloma, and OPN-9840, an oral, non-covalent TEAD inhibitor in malignant mesothelioma and metastatic melanoma. Data were...
SINGAPORE – Keeping blood pressure in check could save lives among Asian adults with type 2 diabetes, suggests a sizable new study of more than 80,000 patients in Singapore. But how low should it go? A new study led by Duke-NUS Medical School—published in the Journal of the American Heart...
BEIJING & CAMBRIDGE, Mass. – CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing innovative drugs to treat rare diseases and rare cancers in China and globally, announced that it has entered into a strategic collaboration and licensing agreement with LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company...